Profile for Japan Patent: 6572891

US Patent Family Members and Approved Drugs for Japan Patent: 6572891

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 10, 2035	Ocuvex Therap	OMLONTI	omidenepag isopropyl

Key insights for pharmaceutical patentability - Japan patent JP6572891

Last updated: April 24, 2026

What does JP6572891 cover, and what does it mean for the Japan drug patent landscape?

JP6572891 is a Japan patent publication that (based on bibliographic placement and numbering conventions) is associated with the modern JPO publication system and sits in the same operational space as drug-indication, formulation, and process filings. However, a complete, claim-level “scope and claims” and a reliable landscape map require the exact JP6572891 record content (application title, assignee, priority, IPC/CPC, legal status, claim text, and citations). Without that record, any attempt to describe the claims, dependency structure, or infringement-relevant scope would be inaccurate.

No response is provided because the underlying JP6572891 patent document text and bibliographic record are not available in the prompt.

Key Takeaways

• A claim-level scope analysis for JP6572891 requires the official JP6572891 publication record and claim text.
• A Japan landscape view requires assignee, priority chain, legal status, cited prior art, and related family members for accurate mapping.
• The prompt does not include the JP6572891 document content needed to produce a complete and accurate analysis.

FAQs

1. Can I identify the drug product or indication for JP6572891 from the patent number alone?
2. Can I describe the independent claims without the claim text?
3. Can I build a defensible landscape without knowing the priority and assignees?
4. Can I list relevant forward citations and family members without the publication record?
5. Can I assess freedom-to-operate relevance without knowing claim scope and legal status?

References

[1] No sources were provided in the prompt.